ReNeuron Group plc Block Listing Review and TVR (3153Z)

TIDMRENE

RNS Number : 3153Z

ReNeuron Group plc

31 August 2018

 
 31 August 2018   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

 
 Name:                              ReNeuron Group plc 
 Name of Scheme:                    ReNeuron Share Option Schemes 
                                   ------------------------------- 
 Period of Return:                  From 1 March 2018 to 31 August 
                                     2018 
                                   ------------------------------- 
 Balance of unallotted securities   902,825 Ordinary Shares (of 
  under scheme(s) from previous      1p each) 
  return: 
                                   ------------------------------- 
 Plus: The amount by which          N/A 
  the block scheme(s) has been 
  increased since the date 
  of the last Review (if any 
  increase has been applied 
  for): 
                                   ------------------------------- 
 Less: Number of securities 
  issued/allotted under scheme(s)     N/A 
  during period 
                                   ------------------------------- 
 Equals: Balance under scheme(s)    902,825 Ordinary Shares 
  not yet issued/allotted at 
  end of period: 
                                   ------------------------------- 
 Number and class of securities     20,000 ordinary shares on 
  originally admitted and the        13 May 2010 
  date of admission: 
                                   ------------------------------- 
 

Total Voting Rights

The Company has 31,646,186 Ordinary Shares in issue, all with voting rights. The Company holds no Ordinary Shares in treasury. The figure of 31,646,186 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

ENDS

ENQUIRIES:

 
ReNeuron                                                                  [phone] 
Olav Hellebø , Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                                  [phone] 
Mark Court, Sophie Wills, Tilly Abraham 
Stifel Nicolaus Europe Limited                                            [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) 
Nplus1 Singer Advisory LLP                                                [phone] 
Mark Taylor (Joint Broker) 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCBSGDIUUXBGIG

(END) Dow Jones Newswires

August 31, 2018 02:00 ET (06:00 GMT)